Key Benefits

• Check stroke risk from artery-clogging particles and inflammation in your blood.
• Spot high ApoB that signals many plaque-forming particles, raising stroke risk.
• Flag elevated LDL and low HDL patterns linked with faster artery plaque buildup.
• Clarify hidden, inherited risk with Lp(a), a common driver of early plaque.
• Guide treatment intensity using ApoB and LDL to hit guideline risk thresholds.
• Track inflammation with hs-CRP to gauge residual risk beyond cholesterol control.
• Add context with NLR and MLR; emerging inflammation markers, not standalone treatment targets.
• Personalize prevention by combining results with blood pressure, diabetes, and smoking status.

What are Stroke biomarkers?

Stroke biomarkers are measurable signals in blood that reflect injury to the brain or its circulation. When a blood vessel in the brain is blocked or bleeds, brain cells and support cells release proteins, and the body’s clotting and immune systems switch on. Testing for these markers can help flag brain injury early, hint at the type of stroke, and track the extent and evolution of damage and repair. Examples include proteins from injured astrocytes and glia (GFAP, S100B), from neurons and axons (NSE, neurofilament light), and signals of clot formation and breakdown (D-dimer, fibrin degradation products) or vascular stress and inflammation (CRP, cytokines). These molecules rise and fall over hours to days, offering a timeline of the event and its aftermath. In practice, blood-based biomarkers complement imaging and examination by adding biological context: they can support rapid triage, guide decisions about clot-busting or bleeding risks, and monitor secondary injury and recovery. In short, they translate microscopic brain events into accessible, actionable information.

Why is blood testing for Stroke important?

Stroke biomarkers show how ready arteries and blood are to form brain‑blocking clots. They reflect two engines: atherogenic lipoproteins that build plaque and inflammatory immune tone that destabilizes plaques across liver‑vessel‑immune systems.For lipids, lower is safer: LDL ideally under 100; risk rises above 130 and especially 160. ApoB (particle count) is lower‑better, often under 80–90; risk up above 100. HDL protects when higher—above 40 in men, 50 in women; 60 often favorable. Lp(a) is genetic: below 30 is common; 50 or higher adds risk. Inflammation markers: hs‑CRP under 1 low, 1–3 average, over 3 high. NLR ~1–3; higher shows stressed innate immunity. MLR ~0.2–0.3; higher links to atherosclerosis. Pregnancy raises hs‑CRP, NLR, and Lp(a); children often have lower LDL/ApoB.Low LDL, ApoB, Lp(a), hs‑CRP, NLR, and MLR signal fewer plaque‑seeding particles and a quieter immune state—lower ischemic stroke risk, typically no symptoms. Extremely low LDL/ApoB from rare genetics can accompany fat‑soluble vitamin issues. Very low leukocyte ratios with infections may reflect immunosuppression. Low HDL is different: it often signals insulin resistance and relates to higher stroke risk; thresholds are lower in men than women.Together, these tests link lipid transport, endothelial health, and innate immunity—the networks that shape brain‑artery disease over decades. Alongside blood pressure, glucose, kidney function, heart rhythm, and family history, they sharpen risk estimation and long‑term outlook.

What insights will I get?

Stroke blood testing provides a window into the health of your cardiovascular and immune systems—two key players in brain function, energy, and overall resilience. At Superpower, we measure LDL, HDL, ApoB, Lp(a), hs-CRP, NLR, and MLR to assess your risk landscape for stroke. These biomarkers help us understand how well your body manages blood flow, inflammation, and vessel stability, all of which are crucial for protecting the brain from injury.LDL (low-density lipoprotein) and ApoB (apolipoprotein B) reflect the amount and type of cholesterol-carrying particles that can contribute to plaque buildup in arteries, a major risk factor for stroke. HDL (high-density lipoprotein) helps remove cholesterol from the bloodstream, offering some protection. Lp(a), or lipoprotein(a), is a genetic variant of LDL that can further increase stroke risk by promoting clot formation and arterial damage. hs-CRP (high-sensitivity C-reactive protein) is a marker of systemic inflammation, which can destabilize blood vessels. NLR (neutrophil-to-lymphocyte ratio) and MLR (monocyte-to-lymphocyte ratio) are indicators of immune system activity and inflammation, both of which can influence stroke risk and recovery.Optimal levels of these markers suggest stable blood vessels, balanced immune responses, and efficient cholesterol transport—all essential for reducing the likelihood of stroke and supporting healthy brain function. When these markers are out of range, it may signal increased vulnerability to vascular injury or inflammation.Interpretation of these results depends on factors like age, sex, genetics, current illness, medications, and even recent infections. Laboratory methods and reference ranges can also vary, so results are best understood in context.